These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 21633718)
1. Pharmacoperone identification for therapeutic rescue of misfolded mutant proteins. Conn PM; Janovick JA Front Endocrinol (Lausanne); 2011 Mar; 2(6):. PubMed ID: 21633718 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs. Janovick JA; Park BS; Conn PM PLoS One; 2011; 6(7):e22784. PubMed ID: 21818389 [TBL] [Abstract][Full Text] [Related]
3. A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor. Conn PM; Smith E; Spicer T; Chase P; Scampavia L; Janovick JA Assay Drug Dev Technol; 2014 May; 12(4):238-46. PubMed ID: 24831790 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic rescue of misfolded/mistrafficked mutants: automation-friendly high-throughput assays for identification of pharmacoperone drugs of GPCRs. Smithson DC; Janovick JA; Conn PM Methods Enzymol; 2013; 521():3-16. PubMed ID: 23351731 [TBL] [Abstract][Full Text] [Related]
5. Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy. Janovick JA; Stewart MD; Jacob D; Martin LD; Deng JM; Stewart CA; Wang Y; Cornea A; Chavali L; Lopez S; Mitalipov S; Kang E; Lee HS; Manna PR; Stocco DM; Behringer RR; Conn PM Proc Natl Acad Sci U S A; 2013 Dec; 110(52):21030-5. PubMed ID: 24324164 [TBL] [Abstract][Full Text] [Related]
6. High-throughput screen for pharmacoperones of the vasopressin type 2 receptor. Conn PM; Smith E; Hodder P; Janovick JA; Smithson DC J Biomol Screen; 2013 Sep; 18(8):930-7. PubMed ID: 23640875 [TBL] [Abstract][Full Text] [Related]
7. Pharmacoperones for Misfolded Gonadotropin Receptors. Newton CL; Anderson RC Handb Exp Pharmacol; 2018; 245():111-134. PubMed ID: 29043503 [TBL] [Abstract][Full Text] [Related]
8. Receptor antagonism/agonism can be uncoupled from pharmacoperone activity. Janovick JA; Spicer TP; Smith E; Bannister TD; Kenakin T; Scampavia L; Conn PM Mol Cell Endocrinol; 2016 Oct; 434():176-85. PubMed ID: 27389877 [TBL] [Abstract][Full Text] [Related]
9. Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs. Conn PM; Ulloa-Aguirre A Trends Endocrinol Metab; 2010 Mar; 21(3):190-7. PubMed ID: 20005736 [TBL] [Abstract][Full Text] [Related]
10. Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules. Ulloa-Aguirre A; Conn PM Curr Drug Targets; 2016; 17(13):1471-81. PubMed ID: 26953247 [TBL] [Abstract][Full Text] [Related]
11. Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens. Conn PM; Smithson DC; Hodder PS; Stewart MD; Behringer RR; Smith E; Ulloa-Aguirre A; Janovick JA Pharmacol Res; 2014 May; 83():38-51. PubMed ID: 24373832 [TBL] [Abstract][Full Text] [Related]
12. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Conn PM; Ulloa-Aguirre A; Ito J; Janovick JA Pharmacol Rev; 2007 Sep; 59(3):225-50. PubMed ID: 17878512 [TBL] [Abstract][Full Text] [Related]
13. Use of pharmacoperones to reveal GPCR structural changes associated with constitutive activation and trafficking. Janovick JA; Conn PM Methods Enzymol; 2010; 485():277-92. PubMed ID: 21050923 [TBL] [Abstract][Full Text] [Related]
14. Rescue of mutant gonadotropin-releasing hormone receptor function independent of cognate receptor activity. Smith E; Janovick JA; Bannister TD; Shumate J; Ganapathy V; Scampavia L; Spicer TP Sci Rep; 2020 Jun; 10(1):10579. PubMed ID: 32601341 [TBL] [Abstract][Full Text] [Related]